GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Excelsior Biopharma Inc (ROCO:6496) » Definitions » Cyclically Adjusted Revenue per Share

Excelsior Biopharma (ROCO:6496) Cyclically Adjusted Revenue per Share : NT$33.25 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Excelsior Biopharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Excelsior Biopharma's adjusted revenue per share for the three months ended in Mar. 2025 was NT$4.572. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$33.25 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Excelsior Biopharma's average Cyclically Adjusted Revenue Growth Rate was -2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-25), Excelsior Biopharma's current stock price is NT$25.60. Excelsior Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was NT$33.25. Excelsior Biopharma's Cyclically Adjusted PS Ratio of today is 0.77.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Excelsior Biopharma was 1.02. The lowest was 0.74. And the median was 0.85.


Excelsior Biopharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Excelsior Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Excelsior Biopharma Cyclically Adjusted Revenue per Share Chart

Excelsior Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 34.02 33.30

Excelsior Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.23 34.02 33.68 33.30 33.25

Competitive Comparison of Excelsior Biopharma's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Excelsior Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Excelsior Biopharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Excelsior Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Excelsior Biopharma's Cyclically Adjusted PS Ratio falls into.


;
;

Excelsior Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Excelsior Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=4.572/134.9266*134.9266
=4.572

Current CPI (Mar. 2025) = 134.9266.

Excelsior Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 7.288 100.684 9.767
201509 7.307 100.392 9.821
201512 7.351 99.792 9.939
201603 7.364 100.470 9.889
201606 7.412 101.688 9.835
201609 9.027 101.861 11.957
201612 9.031 101.863 11.962
201703 9.324 102.862 12.230
201706 8.915 103.349 11.639
201709 9.380 104.136 12.153
201712 8.941 104.011 11.599
201803 8.900 105.290 11.405
201806 9.284 106.317 11.782
201809 8.964 106.507 11.356
201812 8.435 105.998 10.737
201903 7.863 107.251 9.892
201906 8.234 108.070 10.280
201909 7.840 108.329 9.765
201912 9.007 108.420 11.209
202003 7.398 108.902 9.166
202006 8.265 108.767 10.253
202009 7.968 109.815 9.790
202012 6.137 109.897 7.535
202103 6.165 111.754 7.443
202106 6.708 114.631 7.896
202109 6.470 115.734 7.543
202112 7.971 117.630 9.143
202203 3.787 121.301 4.212
202206 3.369 125.017 3.636
202209 3.842 125.227 4.140
202212 3.187 125.222 3.434
202303 4.100 127.348 4.344
202306 4.103 128.729 4.301
202309 4.065 129.860 4.224
202312 4.453 129.419 4.642
202403 4.121 131.776 4.220
202406 4.674 132.554 4.758
202409 4.696 133.029 4.763
202412 5.150 133.157 5.218
202503 4.572 134.927 4.572

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Excelsior Biopharma  (ROCO:6496) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Excelsior Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=25.60/33.25
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Excelsior Biopharma was 1.02. The lowest was 0.74. And the median was 0.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Excelsior Biopharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Excelsior Biopharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Excelsior Biopharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
Zhongxiao E. Road, 5Floor, No.508, Sector 7, Nangang District, Taipei, TWN, 11561
Excelsior Biopharma Inc is mainly engaged in western medicines, importing and exporting of Active Pharmaceutical Ingredients, food, cosmecteuticals and development of cosmetics, research, importing, and exporting of technologies, pharmaceutical technologies transfer and cooperative development and improvement. Geographically, it derives revenue from Taiwan, China and others, with majority of revenue earned from Taiwan.

Excelsior Biopharma Headlines

No Headlines